Figure 2: Estimated crude and adjusted rate ratios (with 95% CI) of sumatriptan use for the treatment of migraine attack. Receiving sumatriptan at all constituted a hurdle in SHI, whereas among sumatriptan users, frequency and intensity of use differed only minimally by health insurance-status.